2 April 2020
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Correction - PDMR Dealing
The following amendment has been made to the 'Director/PDMR Shareholding' announcement released on 23 March 2020 at 15.21 under RNS No 2553H.
Vulpes Testudo Fund, which is controlled by Non-Executive Director, Stephen Diggle, purchased a further 26,000 Ordinary Shares of 1 pence each at a price of 51.8p per share on 19 March 2020.
Through the holdings of Vulpes Life Sciences Fund and Vulpes Testudo Fund, Stephen Diggle is interested in 12,061,670 Ordinary Shares, representing approximately 13.03% of the Company's current issued share capital.
All other details remain unchanged. The full amended text is shown below.
23 March 2020
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
PDMR Dealing
Oxford BioDynamics Plc (AIM: OBD) announces that it has today received notice that Vulpes Testudo Fund, which is controlled by Non-Executive Director, Stephen Diggle, has purchased 26,000 Ordinary Shares of 1 pence each ("shares") at a price of 51.8p per share on 19 March 2020 and a further 15,000 shares at a price of 56.0p per share on 20 March 2020.
Following these transactions, Vulpes Testudo Fund is interested in 251,000 Ordinary Shares, representing 0.27% of the Company's current issued share capital. Through the holdings of Vulpes Life Sciences Fund and Vulpes Testudo Fund, Stephen Diggle is interested in 12,061,670 shares, representing approximately 13.03% of the Company's current issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:
1 |
Details of the person discharging managerial responsibilities/person closely associated |
a) |
Name |
Stephen Diggle |
2 |
Reason for the notification |
a) |
Position/status |
Director/PDMR |
b) |
Initial notification/ Amendment |
Initial notification |
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
a) |
Name |
Oxford BioDynamics Plc |
b) |
LEI |
2138005Y1TK258O5U928 |
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 1 pence each ISIN: GB00BD5H8572 |
b) |
Nature of the transaction |
Acquisition of ordinary shares |
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
0.56 |
15,000 |
0.518 |
26,000 |
|
d) |
Aggregated information - Aggregated volume - Price |
Price |
Volume |
0.533 |
41,000 |
|
e) |
Dates of the transactions |
19 March 2020; and 20 March 2020 |
f) |
Place of the transaction |
Outside a trading venue |
For further details please contact:
Oxford BioDynamics Plc Jon Burrows, CEO Paul Stockdale, CFO |
+44 (0)1865 518910 |
Shore Capital Nominated Adviser and Broker Stephane Auton Edward Mansfield John More |
+44 (0)20 7408 4090 |
FTI Consulting Financial Public Relations Adviser Natalie Garland-Collins |
+44 (0)20 3727 1000 |
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers, based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch™, offers non-invasive liquid biopsy readouts to the standards of validated predictive, prognostic and diagnostic patient stratifications, and aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ offers non-invasive molecular read-outs with strong links to clinical outcomes, and helps reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.
The Company is headquartered in the UK and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.
